Clinical trial NCT01151670: Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
Official title: Use of Pioglitazone for the Prevention of Radiation-Induced Cognitive Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Brain Neoplasms, Malignant
Brain Neoplasms, Benign
Malignant Meningioma
Glioblastoma Multiforme
Anaplastic Astrocytoma
Keywords: radiation therapy
cognitive dysfunction
brain tumor
memory problems
short term memory loss
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2010-06-28
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: RATIONALE: Pioglitazone hydrochloride may be effective treatment for cognitive dysfunction caused by radiation therapy.

PURPOSE: This phase I trial is studying the side effects and best dose of pioglitazone hydrochloride in preventing radiation-induced cognitive dysfunction in treating patients with brain tumors.

Detailed description: PRIMARY OBJECTIVE:

I. To evaluate the tolerability and toxicity associated with two different dose regimens of pioglitazone administered orally as a cytoprotective agent against radiation-induced brain injury.

SECONDARY OBJECTIVE:

I. To evaluate the effect of pioglitazone on glycemic levels and hemoglobin A1c values when pioglitazone is used as a cytoprotective agent concurrent with radiotherapy in normoglycemic patients.

OUTLINE: Patients undergo fractionated external beam radiotherapy, 3-D conformal radiotherapy, or intensity-modulated radiotherapy. Patients receive oral pioglitazone hydrochloride once daily before for 1 week prior to brain irradiation, during and and continuing for 6 months after completion of radiation radiotherapy. After completion of study treatment, patients are followed periodically.

Eligibility criteria: Inclusion Criteria:

* Patients must have histologically or cytologically confirmed brain tumors of the following types: Group 1: malignant brain tumors (glioblastoma multiforme, anaplastic gliomas, brain metastases, and other malignant brain tumors); or Group 2: low grade brain tumors (low grade gliomas, meningiomas, and other low grade brain tumors)
* All stages and grades of brain tumors are eligible
* Patients must have an ECOG performance status of 0-2
* Patients must have agreed to be treated with fractionated, external beam radiation treatment (EBRT) with either curative or palliative intent (the length of the radiation course must at least be ten fractions)
* Patients must have agreed to have CT and MR imaging for purposes of radiation treatment planning, radiation treatment monitoring, and/or radiation treatment evaluation
* Patients must have measurable disease and/or relevant anatomic features using Magnetic Resonance Imaging
* Prior therapies (cytotoxic, surgery, and radiation) are acceptable
* Use of steroids is acceptable when indicated
* Patients must be able to understand and willingly give informed written consent to participate
* Women of childbearing potential must not be pregnant or nursing and must use medically appropriate contraception if sexually active
* Patients must have a life expectancy of greater than 3 months
* Patients must be willing to comply with an oral treatment regimen and be able to swallow oral study tablets

Exclusion Criteria:

* History of allergic reactions to pioglitazone or any other member of the thiazolidinedione family
* Current diagnosis of diabetes as defined by fasting blood sugar \> 125, treatment with anti-diabetic medications, or history of diabetes
* Patients who take insulin
* Patients who have NYHA class III or IV heart failure
* Patients who have elevated transaminases (AST or ALT \> 2.5 times normal limit)
* Patients who have significantly impaired renal function (creatinine \>= 1.5)
* Patients who are significantly anemic (hematocrit \< 33% in men, or \< 30% in women)
* Patients who have symptomatic edema (\>= grade 2)
* Patients who are on medications that have been shown to have a drug interaction with pioglitazone: atorvastatin (doses \> 80 mg/day), systemic anti-fungals, medications with significant CYP 3A4 inhibiting properties
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac, arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant women are excluded from this study if their pregnancy precludes radiation treatment because ionizing radiation used in radiation treatment is an agent with known potential for teratogenic or abortifacient effects
* Patients with psychiatric or social illnesses that may impair compliance with the trial requirements

Primary outcomes:
measure: Best tolerated dose of 2 different doses of orally administered pioglitazone
timeFrame: From first dose to 1 day after last dose of drug
Secondary outcomes:
measure: Toxicities associated with both dose levels
timeFrame: From first dose to 1 day after last dose of drug
measure: To evaluate the effect of pioglitazone on glycemic levels and hemoglobin A1c values when pioglitazone is used as a cytoprotective agent concurrent with radiotherapy in normoglycemic patients.
timeFrame: From first dose to 1 day after last dose of drug
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: Michael Chan
role: PRINCIPAL_INVESTIGATOR
References: